GABA-A receptor · PROTEIN COMPLEX GROUP · Sarcoptes scabiei
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14GABA-A receptor shows approved-linked disease relevance led by parasitic infection. 1 more disease program remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt H9U2V9. Start with parasitic infection, then reuse UniProt H9U2V9 as the stable protein anchor across project notes and exports.
Start with parasitic infection, then reuse UniProt H9U2V9 as the stable protein anchor across project notes and exports.
GABA-A receptor shows approved-linked disease relevance led by parasitic infection. 1 more disease program remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with parasitic infection because it currently carries approved-linked support. Linked drugs include LINDANE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyGamma-aminobutyric acid receptor subunit beta
Review this target as GABA-A receptor, mapped to UniProt H9U2V9. ChEMBL maps the protein component as Gamma-aminobutyric acid receptor subunit beta. Sequence length is 812 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats GABA-A receptor as ChEMBL target CHEMBL2364024, mapped to UniProt H9U2V9. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether GABA-A receptor is the right protein anchor across sources, using UniProt H9U2V9 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why parasitic infection is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | GABA-A receptor |
| Target Type | PROTEIN COMPLEX GROUP |
| Organism | Sarcoptes scabiei |
| UniProt | H9U2V9 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Gamma-aminobutyric acid receptor subunit beta |
| UniProt Accession | H9U2V9 |
| Component Type | Protein |
| Sequence Length | 812 aa |
Gamma-aminobutyric acid receptor subunit beta
Review this target as GABA-A receptor, mapped to UniProt H9U2V9. ChEMBL maps the protein component as Gamma-aminobutyric acid receptor subunit beta. Sequence length is 812 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
GABA-A receptor shows approved-linked disease relevance led by parasitic infection. 1 more disease program remain visible in the same review block.
Start review with parasitic infection because it currently carries approved-linked support. Linked drugs include LINDANE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.